Prokarium and Ginkgo Bioworks Announce Partnership to Discover Multiple Targets for RNA Therapeutics and Immuno-oncology

LONDON, UK and BOSTON, MA — January 9, 2023 — Prokarium, a biopharmaceutical
company pioneering the oncology field of microbial immunotherapy, and Ginkgo Bioworks
(NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today
announced a partnership to develop a bactofection platform to deliver RNA-based therapeutics.

Most gene therapies today leverage viral delivery systems. While significant advances have
been made to optimize these systems, toxicity and targeting issues in connection with these
delivery vehicles may limit their broader utility. Bactofection, the process of transferring genetic
material into a mammalian cell via a bacterium, is an alternative gene delivery system that could
deliver therapeutic agents to a patient.

In bactofection, the naturally occurring tumor-colonizing characteristics of bacterial species,
such as Salmonella, can be modified via genetic manipulation and harnessed to be a targeted
delivery vehicle for various therapeutic payloads. In collaboration with Prokarium, Ginkgo will
aim to engineer a Salmonella-based bactofection platform for the delivery of RNA payloads to
treat cancer patients, building on existing capabilities in RNA therapeuticsviral-based gene therapy and bacterial therapeutics.

“By leveraging Ginkgo’s microbial and mammalian foundry capabilities, we are building a highly
versatile and innovative bactofection platform to support delivery of novel modalities from the
ground up,” said Kristen Albright, CEO at Prokarium. “Through this partnership, we are working
to unlock a new generation of immuno-oncology therapeutics.”

“Advancements in immunotherapy such as checkpoint inhibitors and CAR-T have transformed
the treatment of certain cancers, with tremendous progress across novel modalities continuing
to build,” said Ena Cratsenburg, Chief Business Officer at Ginkgo Bioworks. “With Prokarium,
Ginkgo will work to develop a bactofection platform that leverages the convergence of these
advancements in immuno-oncology, gene therapy, RNA therapeutics and bacterial therapeutics.
Ginkgo is excited to bolster its work with leading companies like Prokarium, which can utilize
Ginkgo’s services to innovate and expand what is possible with novel therapeutics.”

About Prokarium

Prokarium is a biopharmaceutical company leading the oncology field of microbial
immunotherapy. The Company’s pipeline is designed to unlock a new generation of immunooncology therapeutics by re-engineering evolution into a synthetic biology platform. Prokarium’s
lead program is focused on transforming the treatment paradigm in bladder cancer by
orchestrating immune-driven, long-lasting antitumor effects. Prokarium is based in London, UK.
For further information, visit https://www.prokarium.com.

About Ginkgo Bioworks

Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, endto-end services that solve challenges for organizations across diverse markets, from food and
agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo’s biosecurity and
public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to
empower governments, communities, and public health leaders to prevent, detect and respond
to a wide variety of biological threats. For more information, visit ginkgobioworks.com and
concentricbyginkgo.com, read our blog, or follow us on social media channels such as Twitter (@Ginkgo and @ConcentricByGBW), Instagram (@GinkgoBioworks and @ConcentricByGinkgo), or LinkedIn.

Forward-Looking Statements of Ginkgo Bioworks

This press release contains certain forward-looking statements within the meaning of the federal
securities laws, including statements regarding the capabilities and potential success of the
partnership and Ginkgo’s cell programming platform. These forward-looking statements
generally are identified by the words “believe,” “can,” “project,” “potential,” “expect,” “anticipate,”
“estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,”
“will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements
are predictions, projections and other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks and uncertainties. Many
factors could cause actual future events to differ materially from the forward-looking statements
in this press release, including but not limited to: (i) volatility in the price of Ginkgo’s securities
due to a variety of factors, including changes in the competitive and highly regulated industries
in which Ginkgo operates and plans to operate, variations in performance across competitors,
and changes in laws and regulations affecting Ginkgo’s business, (ii) the ability to implement
business plans, forecasts, and other expectations, and to identify and realize additional
business opportunities, (iii) the risk of downturns in demand for products using synthetic biology,
(iv) the unpredictability of the duration of the COVID-19 pandemic and the demand for COVID19 testing and the commercial viability of our COVID-19 testing business, (v) changes to the
biosecurity industry, including due to advancements in technology, emerging competition and
evolution in industry demands, standards and regulations, and (vi) our ability to realize the
expected benefits of merger and acquisition transactions. The foregoing list of factors is not
exhaustive. You should carefully consider the foregoing factors and the other risks and
uncertainties described in the “Risk Factors” section of Ginkgo’s quarterly report on Form 10-Q
filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 14, 2022
and other documents filed by Ginkgo from time to time with the SEC. These filings identify and
address other important risks and uncertainties that could cause actual events and results to
differ materially from those contained in the forward-looking statements. Forward-looking
statements speak only as of the date they are made. Readers are cautioned not to put undue
reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend
to update or revise these forward-looking statements, whether as a result of new information,
future events, or otherwise. Ginkgo does not give any assurance that it will achieve its
expectations.

PROKARIUM CONTACT:
Lisa Stone
lisa.stone@prokarium.com

GINKGO BIOWORKS INVESTOR CONTACT:
investors@ginkgobioworks.com

GINKGO BIOWORKS MEDIA CONTACT:
press@ginkgobioworks.com

Related News

LONDON, UK, March 14, 2024 – Prokarium announces they have been awarded a UK Research and Innovation (UKRI) Engineering Biology...
London, UK – February 7, 2024 –  Prokarium, a clinical-stage biopharmaceutical company bioengineering Living Cures through cutting-edge synthetic...
London, UK – February 7, 2024 –  Prokarium, a clinical-stage biopharmaceutical company bioengineering Living Cures through cutting-edge synthetic...
London, UK – November 2, 2023 – Prokarium, a biopharmaceutical company at the forefront of applying synthetic biology to create...
London, UK – November 2, 2023 – Prokarium, a biopharmaceutical company at the forefront of applying synthetic biology to create...